Monday , December 11 2017
Home / Production Assistant, Diabetes In Control (page 13)

Production Assistant, Diabetes In Control

Impaired Renal Function

Test Your Knowledge

At her last visit, your patient’s labs showed a eGFR 55 ml/min/1.73 m2. At this visit, her labs measured an eGFR of 44 ml/min/1.73 m2. Dose reduction/cessation should be considered for all of the following agents EXCEPT: A. Glyburide B. Sitaglipitin C. Metformin D. Pioglitazone Follow the link for the correct answer.

Read More »

Prediabetes Drug Recommendations

What percentage of your prediabetes patients do you recommend a pharmaceutical treatment? 1. 10-25% 2. 25-50% 3. Greater than 50% 4. Zero. I only recommend diet and exercise. Follow the link to share your response.

Read More »

International Textbook of Diabetes Mellitus, 4th Ed., Excerpt #89: Lipid and Lipoprotein Metabolism, Hypolipidemic Agents, and Therapeutic Goals Part 1

Any discussion of lipid and lipoprotein metabolism in diabetes mellitus, especially type 2 diabetes mellitus (T2DM), must consider the role of insulin resistance (IR). IR plays a central role in the abnormal lipid and lipoprotein metabolism of T2DM [1] as evidenced by the characteristic set of lipid and lipoprotein abnormalities accompanying IR, even in the absence of frank hyperglycemia or abnormal glucose tolerance. Individuals with IR have low plasma levels of HDL-C and elevations in plasma triglyceride (TG) levels compared with levels seen in individuals who have normal insulin sensitivity. There is also an increase in the proportion of low-density lipoprotein (LDL) particles that are small, dense, and cholesterol ester-poor. I

Read More »